Preparation of heparinized acellular vascular scaffold and hemocompatibility evaluation

doi:10.12307/2024.479

Abstract

Abstract: BACKGROUND: Acellular vascular scaffolds can mimic the microstructure and function of native blood vessels, but some extracellular matrix loss occurs during their preparation, which affects their hemocompatibility. Therefore, it is necessary to modify them to improve their hemocompatibility.
OBJECTIVE: To assess the hemocompatibility of acellular vascular scaffold prepared by Triton-x100/heparin sodium treatment.
METHODS: The abdominal aorta was taken from SD rats and randomly divided into control and experimental groups. The control group was treated with Triton-x100 for 48 hours. The experimental group was treated with Triton-x100 for 48 hours and then treated with heparin sodium. The morphology and hydrophilicity of the two groups of acellular vascular scaffolds were detected. The hemocompatibility of the two groups of acellular vascular scaffold was evaluated by recalcification coagulation time test, platelet adhesion test, dynamic coagulation time test, hemolysis test, and complement activation test.
RESULTS AND CONCLUSION: (1) Scanning electron microscopy showed that the surface of the two groups of vascular scaffolds was relatively intact, and a large number of fiber filaments appeared on the surface of the scaffolds after decellularity treatment, and the surface microstructure changed significantly. The water contact angle of the two groups of vascular scaffolds was smaller than that of natural vessels (P < 0.000 1). There was no significant difference in water contact angle between the two groups (P > 0.05). (2) The coagulation time of vascular scaffold was longer in the experimental group than in the control group (P < 0.05). The number of platelets attached to the scaffold membrane was less in the experimental group than that in the control group (P < 0.000 1). The coagulation index was greater in the experimental group than that in the control group (P < 0.01), and the complement level was lower in the experimental group than that in the control group (P < 0.001). The hemolysis rate of the two groups was lower than 5% of the national standard. (3) To conclude, acellular scaffold treated with Triton-x100/heparin sodium has excellent hemocompatibility.

Key words: acellular vascular scaffold, heparinization, hemocompatibility, cardiovascular disease, tissue engineering

CLC Number:

Li Xiafei, Zhao Lingling, Liang Feng, Zhang Xuewei, Zhang Jinjin, Lin Fei, Yang Tuo, Zhao Liang. Preparation of heparinized acellular vascular scaffold and hemocompatibility evaluation[J]. Chinese Journal of Tissue Engineering Research, 2024, 28(17): 2631-2636.

Figures/Tables 9

References

[1] AWAD N K, NIU H, ALI U, et al. Electrospun fibrous scaffolds for small-diameter blood vessels: a review. Membranes (Basel). 2018;8(1):15.
[2] JI J, XU H, LI C, et al. Small-Caliber Tissue-Engineered Vascular Grafts Based on Human-Induced Pluripotent Stem Cells: Progress and Challenges. Tissue Eng Part B Rev. 2023;29(4):441-455.
[3] FLIS A, TRÁVNÍČKOVÁ M, KOPER F, et al. Poly(octamethylene citrate) Modified with Glutathione as a Promising Material for Vascular Tissue Engineering. Polymers (Basel). 2023;15(5):1322.
[4] PASHNEH-TALA S, MACNEIL S, CLAEYSSENS F. The tissue-engineered vascular graft-past, present, and future. Tissue Eng Part B Rev. 2016; 22(1):68-100.
[5] MOHAMMADI F, GOLAFSHAN N, KHARAZIHA M, et al. Chitosan-heparin nanoparticle coating on anodized NiTi for improvement of blood compatibility and biocompatibility. Int J Biol Macromol. 2019;127: 159-168.
[6] ZIZHOU R, WANG X, HOUSHYAR S. Review of Polymeric Biomimetic Small-Diameter Vascular Grafts to Tackle Intimal Hyperplasia. ACS Omega. 2022;7:22125-22148.
[7] ZHANG F, KING MW. Immunomodulation Strategies for the Successful Regeneration of a Tissue-Engineered Vascular Graft. Adv Healthc Mater. 2022;11:e2200045.
[8] OBIWELUOZOR FO, KAYUMOV M, KWAK Y, et al. Rapid remodeling observed at mid-term in-vivo study of a smart reinforced acellular vascular graft implanted on a rat model. J Biol Eng. 2023;17:1.
[9] 刘俊,张晓膺.纳米APS外膜肝素化内膜小口径组织工程血管的实验研究[J].上海交通大学学报(医学版),2017,37(3):337-343.
[10] NEMENO-GUANZON JG, LEE S, BERG JR, et al. Trends in tissue engineering for blood vessels. J Biomed Biotechnol. 2012;2012: 956345.
[11] YAO Y, ZAW AM, ANDERSON DEJ, et al. Fucoidan and topography modification improved in situ endothelialization on acellular synthetic vascular grafts. Bioact Mater. 2023;22:535-550.
[12] BAHRAMZADEH E, YILMAZ E, ADALI T. Chitosan-graft-poly(N-hydroxy ethyl acrylamide) copolymers: Synthesis, characterization and preliminary blood compatibility in vitro. Int J Biol Macromol. 2019;123:1257-1266.
[13] 夏成勇,刘长建,冉峰,等.等离子体处理脱细胞血管支架的血液相容性[J].中国组织工程研究与临床康复,2009,13(21):4033-4036.
[14] DU PC, LI XF, SUN LL, et al. Improved hemocompatibility by modifying acellular blood vessels with bivalirudin and its biocompatibility evaluation. J Biomed Mater Res A. 2022;110(3):635-651.
[15] KOPEC K, WOJASINSKI M, EICHLER M, et al. Polydopamine and gelatin coating for rapid endothelialization of vascular scaffolds. Biomater Adv. 2022;134:112544.
[16] TARDALKAR K, MARSALE T, BHAMARE N, et al. Heparin Immobilization of Tissue Engineered Xenogeneic Small Diameter Arterial Scaffold Improve Endothelialization. Tissue Eng Regen Med. 2022;19:505-523.
[17] YANG F, GUO G, WANG Y. Inflammation-triggered dual release of nitroxide radical and growth factor from heparin mimicking hydrogel-tissue composite as cardiovascular implants for anti-coagulation, endothelialization, anti-inflammation, and anti-calcification. Biomaterials. 2022;289:121761.
[18] LV YM, HUANG HM, WANG QL, et al. Acellular porcine aorta matrix as a novel tissue engineered vascular scaffold biocompatibility and mechanical properties. J Cli Reh Tissue Eng Res. 2010;14(47):8921-8925.
[19] QIU H, QI P, LIU J, et al. Biomimetic engineering endothelium-like coating on cardiovascular stent through heparin and nitric oxide-generating compound synergistic modification strategy. Biomaterials. 2019;207:10-22.
[20] 周莹,肖利吉,姚丽,等.自修复型超疏水材料研究进展[J].材料导报,2019,33(7):159-167.
[21] 高云佳,赵庆春,闵鹏,等.脱皮马勃止血有效部位的实验研究[J].解放军药学学报,2010,26(6):82-84.
[22] 高娟.壳聚糖止血活性及其作用机理的初步研究[D].无锡:江南大学,2009.
[23] 秦静雯,王鸿博,傅佳佳,等.醋纤基载药纳米纤维药物活性评价[J].功能材料,2014,45(14):14077-14080.
[24] 欧阳晨曦,李沁,王维慈,等.小口径人工血管血液相容性[J].中国组织工程研究与临床康复,2008,12(6):133-137.
[25] LIU HF, LI XM, ZHOU G, et al. Electrospun sulfated silk fibroin nanofibrous scaffolds for vascular tissue engineering. Biomaterials. 2011;32:3784-3793.
[26] 陈捷,杨镜秋,刘春晓.灌注法制备全肾脏脱细胞基质支架的体内生物相容性[J].中国组织工程研究,2015,19(16):75-79.
[27] 薛正翔,陈登龙,李敏,等.静电纺丝制备小直径血管支架及其血液相容性的研究[J].功能材料,2009(10):129-132.
[28] 马慧.羟基磷灰石表面构建压电陶瓷涂层的生物相容性研究[D].乌鲁木齐:新疆医科大学,2015.
[29] 贾山山,陈群清,闫玉生.肝素在人工小血管表面改性中的应用[J].中国医学物理学杂志,2018,35(10):126-130.
[30] 马巧,宋文静,冀慧雁,等.血管支架材料的应用及研究现状[J].临床医药实践,2018,27(11):57-62.
[31] 阮烨.冷空气活动对心脑血管疾病相关指标影响的初步研究[D].兰州:兰州大学,2013.
[32] SU H, LIU W, LI X, et al. Cellular energy supply for promoting vascular remodeling of small-diameter vascular grafts: a preliminary study of a new strategy for vascular graft development. Biomater Sci. 2023; 11(9):3197-3213.
[33] OMID H, ABDOLLAHI S, BONAKDAR S, et al. Biomimetic vascular tissue engineering by decellularized scaffold and concurrent cyclic tensile and shear stresses. J Mater Sci Mater Med. 2023;34:12.
[34] 刘桂阳.皮/芯结构的丝素/聚己内酯纤维及其双层血管再生支架[D].苏州:苏州大学,2015.
[35] YAO Y, WANG J, CUI Y, et al. Effect of sustained heparin release from PCL/chitosan hybrid small-diameter vascular grafts on anti-thrombogenic property and endothelialization. Acta Biomater. 2014; 10(6):2739-2749.
[36] 赵亮,李霞飞,李成成,等.应用Triton-x100加丹参酚酸B制备脱细胞血管支架及其血液相容性研究[J].中国生物医学工程学报, 2019,38(2):201-207.
[37] LIU H, LI X, ZHOU G, et al. Electrospun sulfated silk fibroin nanofibrous scaffolds for vascular tissue engineering. Biomaterials. 2011;32(15): 3784-3793.
[38] MONTELIONE N, LORENI F, NENNA A, et al. Tissue Engineering and Targeted Drug Delivery in Cardiovascular Disease: The Role of Polymer Nanocarrier for Statin Therapy. Biomedicines. 2023;11(3):798.
[39] LIU Y, YUAN H, LIU Y, et al. Multifunctional nanoparticle-VEGF modification for tissue-engineered vascular graft to promote sustained anti-thrombosis and rapid endothelialization. Front Bioeng Biotechnol. 2023;11:1109058.
[40] 王学宁,陈长志,杨岷,等.肝素处理小口径脱细胞异种血管的移植研究[J].中华胸心血管外科杂志,2006,22(5):324-325.